US 12139709
Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
granted A61KA61K31/7105A61K9/0019
Quick answer
US patent 12139709 (Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene) held by Sarepta Therapeutics, Inc. expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Sarepta Therapeutics, Inc.
- Grant date
- Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K31/7105, A61K9/0019, A61K9/0053, A61P